NCT05147051 is a Phase 2 clinical trial of Meglumine Sodium Succinate in Metabolic Acidosis, sponsored by POLYSAN Scientific & Technological Pharmaceutical Company.

Who is sponsoring NCT05147051?

NCT05147051 is sponsored by POLYSAN Scientific & Technological Pharmaceutical Company.

What drugs are being tested in NCT05147051?

Interventions in NCT05147051: Meglumine Sodium Succinate, Placebo.

What condition does NCT05147051 study?

NCT05147051 studies Metabolic Acidosis.

Is NCT05147051 still recruiting?

NCT05147051 is currently completed. Last updated 5 October 2022.

Last reviewed 2022-10-05 · How we verify

NCT05147051

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients

Completed Phase 2 Last updated 5 October 2022

What this trial tests

Phase 2 trial testing Meglumine Sodium Succinate in Metabolic Acidosis in 140 participants. Completed in 22 June 2022.

Timeline

16 June 2021

Primary endpoint
23 May 2022

22 June 2022

Quick facts

Lead sponsor	POLYSAN Scientific & Technological Pharmaceutical Company
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	140
Start date	16 June 2021
Primary completion	23 May 2022
Estimated completion	22 June 2022
Sites	6 locations across Russia

Drugs / interventions tested

Meglumine Sodium Succinate — full drug profile →
Placebo

Conditions studied

Metabolic Acidosis — all drugs for Metabolic Acidosis →

Sponsor

POLYSAN Scientific & Technological Pharmaceutical Company — full company profile →

Who can join

Adults 18 to 70, any sex, with Metabolic Acidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An acid-base imbalance, called metabolic acidosis (acid-base disorder lasting from several minutes to several days, caused by a decrease in serum bicarbonate ion (HCO3) concentration), is often observed in critically ill patients with various underlying diseases. Metabolic acidosis has a negative impact on the cardiovascular, respiratory, digestive, nervous, excretory, hematological, endocrine, musculoskeletal and immune systems and is associated with unfavourable outcomes. Reamberin® is a solution of disubstituted sodium salt of succinic acid, which has an alkaline reaction and succinate is capable to integrate into the Krebs cycle and restore energy metabolism in the cell. The aim of the present study is to evaluate the efficacy and safety of meglumine sodium succinate at a dose of 500 to 3000 ml in critically ill patients with metabolic acidosis and choose the optimal volume of its solution for the correction of metabolic acidosis in critically ill patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Metabolic Acidosis

Currently open trials in the same condition.

NCT06366230 — Adding Urea to the Final Dialysis Fluid · Phase 1, PHASE2 · recruiting
NCT06881641 — A Study on Bedside Formate Assay as a Diagnostic Tool in Methanol Poisoning · recruiting
NCT06545565 — Prevention of Metabolic Acidosis in Preterm Neonates by Replacing Sodium Chloride With Sodium Acetate in Parenteral Nutr · Phase 3 · recruiting
NCT06932042 — PLADO for Conservative Management of CKD · NA · recruiting
NCT04984226 — Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD · Phase 2 · recruiting

Other POLYSAN Scientific & Technological Pharmaceutical Company trials

Trials by the same sponsor.

NCT06955416 — REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis · Phase 2, PHASE3 · recruiting
NCT06514976 — Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy · recruiting
NCT06735898 — Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tab · recruiting
NCT06286254 — Study of Safety and Efficacy of the Drug Cycloferone in Patients with Acute Respiratory Viral Infection · completed
NCT06183229 — Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05147051 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by POLYSAN Scientific & Technological Pharmaceutical Company
Last refreshed: 5 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05147051.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing